Windlas Biotech Ltd (WINDLAS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003519,
    "name": "Windlas Biotech",
    "stock_name": "Windlas Biotech",
    "full_name": "Windlas Biotech Ltd",
    "name_url": "stocks-analysis/windlas-biotech",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "769.40",
    "chg": -20.75,
    "chgp": "-2.63%",
    "dir": -1,
    "prev_price": "790.15",
    "mcapval": "1,652.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543329,
    "symbol": "WINDLAS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0H5O01029",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "24.88 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/windlas-biotech-1003519-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Windlas Biotech Sees Revision in Market Assessment Amidst Challenging Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-downgraded-to-sell-by-marketsmojo-amid-weak-performance-3736827",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_mojoScore_3736827.png",
        "date": "2025-11-29 17:52:31",
        "description": "Windlas Biotech has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued stock performance and sector challenges. This adjustment highlights evolving perspectives on the company’s financial health, valuation, and technical outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Windlas Biotech Faces Bearish Technical Trends Amidst Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotechs-technical-trend-shifts-from-mildly-bearish-to-bearish-amid-stock-decline-3696635",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_technicaldot_3696635.png",
        "date": "2025-11-13 08:10:53",
        "description": "Windlas Biotech, a small-cap pharmaceutical company, has faced a challenging year with a return of -16.53%, contrasting with the Sensex's gain. Technical indicators suggest a bearish sentiment, yet the company has shown resilience with a notable 247.73% return over the past three years, outperforming the Sensex significantly."
      },
      {
        "title": "Windlas Biotech Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-forms-death-cross-signaling-potential-bearish-trend-ahead-3693092",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_dealthcross_3693092.png",
        "date": "2025-11-12 18:00:58",
        "description": "Windlas Biotech has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has declined 0.51%, contributing to a one-year performance of -16.53%, while its market capitalization is Rs 1,779.00 crore, with a P/E ratio lower than the industry average."
      },
      {
        "title": "Why is Windlas Biotech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-windlas-biotech-fallingrising-3681620",
        "imagepath": "",
        "date": "2025-11-08 00:10:35",
        "description": "As of 07-Nov, Windlas Biotech Ltd is experiencing a decline in its stock price, currently at Rs 867.80, which represents a decrease of Rs 56.2 or 6.08%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 9.66% during this period. It opened with a loss of 2.6% today and reached an intraday low of Rs 855, reflecting a 7.47% drop. In terms of performance over the past week, the stock has decreased by 7.89%, while its year-to-date return stands at a negative 16.03%. Despite positive quarterly results showing the highest net sales and operating profit margins, the stock's overall performance has been hindered by poor long-term growth and significant underperformance relative to the broader market.\n\nIn the broader market context, Windlas Biotech's recent performance contrasts sharply with the Sensex, which has gained 1.57% over the past month. ..."
      },
      {
        "title": "Are Windlas Biotech latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-windlas-biotech-latest-results-good-or-bad-3680569",
        "imagepath": "",
        "date": "2025-11-07 19:26:39",
        "description": "Windlas Biotech's latest financial results present a mixed picture of operational performance. The company reported record revenue of ₹222.40 crores in Q2 FY26, reflecting a sequential growth of 5.86% and an 18.93% increase year-on-year. This consistent revenue momentum has been evident over the past seven quarters, indicating strong demand for its CDMO services.\n\nHowever, profitability metrics have not kept pace with revenue growth. The operating margin, which stood at 12.84%, showed only a marginal improvement from the previous quarter, while the PAT margin compressed to 8.00%, down from 8.41% in Q1 FY26. This suggests challenges in translating topline growth into bottom-line expansion, raising concerns about operational efficiency and cost management.\n\nThe financial data indicates that employee costs surged significantly, outpacing revenue growth, which contributed to the margin compression. Additionally..."
      },
      {
        "title": "Windlas Biotech Hits Day Low at Rs 863.2 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-hits-day-low-at-rs-8632-amid-price-pressure-3679991",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_priceRelatedfactors_3679991.png",
        "date": "2025-11-07 15:03:53",
        "description": "Windlas Biotech has faced a notable decline, losing 7.35% on November 7, 2025. The stock has underperformed the sector and broader market trends, trading below key moving averages. Year-to-date, it has decreased by 14.96%, contrasting sharply with the Sensex's gain of 6.46%."
      },
      {
        "title": "Windlas Biotech Faces Technical Shift Amidst Mixed Financial Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-stock-downgraded-from-hold-to-sell-by-marketsmojo-3678807",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_mojoScore_3678807.png",
        "date": "2025-11-07 08:28:33",
        "description": "Windlas Biotech, a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical indicators, moving to a mildly bearish trend. Despite a positive quarterly financial performance, the stock has underperformed compared to the broader market over the past year."
      },
      {
        "title": "Windlas Biotech Faces Mixed Technical Trends Amidst Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotechs-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3678705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/WindlasBiotech_technicaldot_3678705.png",
        "date": "2025-11-07 08:09:57",
        "description": "Windlas Biotech, a small-cap pharmaceutical company, has experienced a challenging year with a return of -17.01%, contrasting with the Sensex's modest gain. Despite recent fluctuations, the company has shown resilience with a significant 284.38% return over the past three years, outperforming the Sensex during that period."
      },
      {
        "title": "How has been the historical performance of Windlas Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-windlas-biotech-3677369",
        "imagepath": "",
        "date": "2025-11-06 23:04:07",
        "description": "Answer:\nThe historical performance of Windlas Biotech shows a consistent growth trajectory in net sales and profits over the years, culminating in the latest figures for March 2025.\n\nBreakdown:\nWindlas Biotech has demonstrated significant growth in net sales, increasing from 328.85 Cr in March 2020 to 759.88 Cr in March 2025. This upward trend is mirrored in total operating income, which also rose from 328.85 Cr to 759.88 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 112.13 Cr in March 2025, up from 43.95 Cr in March 2020. Profit before tax has shown a steady increase, climbing from 32.14 Cr in March 2020 to 79.76 Cr in March 2025, while profit after tax reached 60.99 Cr in March 2025, compared to 16.21 Cr in March 2020. The company's total assets have expanded from 337.82 Cr in March 2020 to 760.17 Cr in March 2025, reflecting a robust growth in both cur..."
      }
    ],
    "total": 241,
    "sid": "1003519",
    "stock_news_url": "https://www.marketsmojo.com/news/windlas-biotech-1003519"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Windlas Biotech Ltd has declared <strong>116%</strong> dividend, ex-date: 21 Jul 25",
          "dt": "2025-07-21",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Windlas Biotech Sees Revision in Market Assessment Amidst Challenging Performance

2025-11-29 17:52:31

Windlas Biotech has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters amid a backdrop of subdued stock performance and sector challenges. This adjustment highlights evolving perspectives on the company’s financial health, valuation, and technical outlook within the Pharmaceuticals & Biotechnology sector.

Windlas Biotech Faces Bearish Technical Trends Amidst Market Challenges

2025-11-13 08:10:53

Windlas Biotech, a small-cap pharmaceutical company, has faced a challenging year with a return of -16.53%, contrasting with the Sensex's gain. Technical indicators suggest a bearish sentiment, yet the company has shown resilience with a notable 247.73% return over the past three years, outperforming the Sensex significantly.

Windlas Biotech Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-11-12 18:00:58

Windlas Biotech has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has declined 0.51%, contributing to a one-year performance of -16.53%, while its market capitalization is Rs 1,779.00 crore, with a P/E ratio lower than the industry average.

Why is Windlas Biotech falling/rising?

2025-11-08 00:10:35

As of 07-Nov, Windlas Biotech Ltd is experiencing a decline in its stock price, currently at Rs 867.80, which represents a decrease of Rs 56.2 or 6.08%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 9.66% during this period. It opened with a loss of 2.6% today and reached an intraday low of Rs 855, reflecting a 7.47% drop. In terms of performance over the past week, the stock has decreased by 7.89%, while its year-to-date return stands at a negative 16.03%. Despite positive quarterly results showing the highest net sales and operating profit margins, the stock's overall performance has been hindered by poor long-term growth and significant underperformance relative to the broader market. In the broader market context, Windlas Biotech's recent performance contrasts sharply with the Sensex, which has gained 1.57% over the past month. ...

Are Windlas Biotech latest results good or bad?

2025-11-07 19:26:39

Windlas Biotech's latest financial results present a mixed picture of operational performance. The company reported record revenue of ₹222.40 crores in Q2 FY26, reflecting a sequential growth of 5.86% and an 18.93% increase year-on-year. This consistent revenue momentum has been evident over the past seven quarters, indicating strong demand for its CDMO services. However, profitability metrics have not kept pace with revenue growth. The operating margin, which stood at 12.84%, showed only a marginal improvement from the previous quarter, while the PAT margin compressed to 8.00%, down from 8.41% in Q1 FY26. This suggests challenges in translating topline growth into bottom-line expansion, raising concerns about operational efficiency and cost management. The financial data indicates that employee costs surged significantly, outpacing revenue growth, which contributed to the margin compression. Additionally...

Windlas Biotech Hits Day Low at Rs 863.2 Amid Price Pressure

2025-11-07 15:03:53

Windlas Biotech has faced a notable decline, losing 7.35% on November 7, 2025. The stock has underperformed the sector and broader market trends, trading below key moving averages. Year-to-date, it has decreased by 14.96%, contrasting sharply with the Sensex's gain of 6.46%.

Windlas Biotech Faces Technical Shift Amidst Mixed Financial Performance Indicators

2025-11-07 08:28:33

Windlas Biotech, a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a shift in its technical indicators, moving to a mildly bearish trend. Despite a positive quarterly financial performance, the stock has underperformed compared to the broader market over the past year.

Windlas Biotech Faces Mixed Technical Trends Amidst Market Challenges

2025-11-07 08:09:57

Windlas Biotech, a small-cap pharmaceutical company, has experienced a challenging year with a return of -17.01%, contrasting with the Sensex's modest gain. Despite recent fluctuations, the company has shown resilience with a significant 284.38% return over the past three years, outperforming the Sensex during that period.

How has been the historical performance of Windlas Biotech?

2025-11-06 23:04:07

Answer: The historical performance of Windlas Biotech shows a consistent growth trajectory in net sales and profits over the years, culminating in the latest figures for March 2025. Breakdown: Windlas Biotech has demonstrated significant growth in net sales, increasing from 328.85 Cr in March 2020 to 759.88 Cr in March 2025. This upward trend is mirrored in total operating income, which also rose from 328.85 Cr to 759.88 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 112.13 Cr in March 2025, up from 43.95 Cr in March 2020. Profit before tax has shown a steady increase, climbing from 32.14 Cr in March 2020 to 79.76 Cr in March 2025, while profit after tax reached 60.99 Cr in March 2025, compared to 16.21 Cr in March 2020. The company's total assets have expanded from 337.82 Cr in March 2020 to 760.17 Cr in March 2025, reflecting a robust growth in both cur...

View All News